GLOW BLEND (GHK-Cu, BPC-157, TB500) | 70mg

Product Overview

GLOW BLEND | 70mg (GHK-Cu 50mg, BPC-157 10mg, TB500 10mg)

GLOW BLEND offers a multi-compound research reagent formulated strictly for in vitro and animal model studies. We’ve combined three extensively researched peptides into a single lyophilised vial. This setup gives researchers a practical way to study angiogenic upregulation, cytoskeletal dynamics, and extracellular matrix (ECM) remodelling all at once, rather than running separate isolated assays.

The complex consists of Glycyl-L-histidyl-L-lysine copper(II) (GHK-Cu), Body Protection Compound-157 (BPC-157), and Thymosin Beta-4 derivative (TB500). In a lab setting, combining these specific compounds allows for close observation of cellular resilience, fibroblast migration, and broader structural tissue responses following induced physiological stress.

Technical Specifications

• Compound 1: GHK-Cu (50mg) | Copper-binding tripeptide
• Compound 2: BPC-157 (10mg) | Pentadecapeptide (Gastric derivative)
• Compound 3: TB500 (10mg) | Synthetic Actin-sequestering peptide
• Total Peptide Content: 70mg
• Format: Lyophilised Solid (Sealed Vial)
• Appearance: Pale blue crystalline powder (due to Copper II ion complex)
• Grade: Laboratory / Analytical Grade
• Purity: >99% (HPLC Verified across all three sequences)

Research Mechanism (Mechanism of Action)

Cellular models show this blend operating across three primary pathways:

1. ECM Remodelling (GHK-Cu): GHK-Cu modulates matrix metalloproteinases (MMPs) and their inhibitors. Laboratory assays repeatedly show it stimulating fibroblast-driven synthesis of collagen and elastin. It also promotes the breakdown of irregular scar tissue structures, which is why it remains a staple in dermal and structural tissue research.
2. Angiogenic Upregulation (BPC-157): This pentadecapeptide upregulates Vascular Endothelial Growth Factor (VEGF) expression. When applied to in vitro endothelial models, BPC-157 accelerates the formation of new blood vessels—creating the nutrient pathways required for rapid cellular proliferation.
3. Cytoskeletal Motility (TB500): TB500 binds directly to cellular actin. By sequestering these actin monomers, the peptide facilitates rapid cell migration and survival. This mechanism allows researchers to closely map accelerated tissue response times.

Reconstitution & Handling Guidelines

Because of the unusually high peptide mass (70mg) and the inclusion of the copper ion complex, you need to reconstitute this blend carefully to avoid shearing the peptide bonds:

• Recommended Solvent: Bacteriostatic Reconstitution Solution (0.9% Benzyl Alcohol).
• Procedure: Inject the solvent slowly against the inner wall of the vial rather than directly onto the powder. Do not shake the vial. Roll it gently in a circular motion. Due to the high yield, give it a few extra minutes for the lyophilised solid to dissolve into a clear, slightly blue-tinted liquid.
• Storage: Store the unmixed vial at -20°C. Once reconstituted, refrigerate at 2°C to 8°C and utilise promptly to maintain peptide stability.

WARNING: This product is intended for Laboratory Research Purposes Only. It is not intended for human consumption, diagnostic, or therapeutic use.

Scientific References (External Links)

For researchers seeking primary literature on the mechanisms described above:

Biomedical Research International: “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration” View Study

Journal of Physiology and Pharmacology: “BPC 157 and blood vessels” View Study

Annals of the New York Academy of Sciences: “Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues” View Study